<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668456</url>
  </required_header>
  <id_info>
    <org_study_id>8/8/2020 ANET4</org_study_id>
    <nct_id>NCT04668456</nct_id>
  </id_info>
  <brief_title>Subtenon and Intravenous Dexmedetomidine Effect on Patients Undergoing Cataract Surgery</brief_title>
  <official_title>The Effect of Subtenon and Intravenous Dexmedetomidine on Patients Undergoing Cataract Surgery: A Comparative Randomized Controlled Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study designed to compare the effects and the safety of adding dexmedetomidine to local&#xD;
      anesthetics and its intravenous administration in subtenon block in patients undergoing&#xD;
      cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ophthalmological surgery can be performed under topical, regional or general anesthesia.&#xD;
      Recently, the majority of ocular surgeries performed by regional rather than general&#xD;
      anesthesia, because of the regional anesthesia is more economic, easy to perform, and the&#xD;
      risk involved is less. Orbital regional anesthesia can be done using a retrobulbar&#xD;
      (intra-conal) block, peribulbar (extra-conal) block or sub-Tenon's block.&#xD;
&#xD;
      The STBs or episcleral block was first described by Turnbull in 1884 and it was repopularized&#xD;
      in the 1990s as a simple and safe alternative to needle-based eye blocks. The STB becomes the&#xD;
      most widely practiced regional technique for cataract surgery, because it produces&#xD;
      satisfactory anesthesia for most intraocular procedures, and avoids the inherent risks of&#xD;
      needle-based blocks, such as globe perforation and optic nerve injury.&#xD;
&#xD;
      Dexmedetomidine is a selective α-2 receptor agonist that produces sedation and analgesia&#xD;
      without causing respiratory depression. It also allows patients to respond to verbal commands&#xD;
      during the sedation; easy conversion from sleeping to awakening is possible. Therefore,&#xD;
      dexmedetomidine has been used as sedative in various clinical fields in intensive care unit&#xD;
      and surgery and an adjuvant to local anesthetics.&#xD;
&#xD;
      Many studies were done to evaluate its effect as sedative or anlgesic when administered&#xD;
      either intravenously or when added to local anesthesia in ophthalmic block. But no one, till&#xD;
      now comparing its effect when used as adjuvant to local anesthetics or administered&#xD;
      intravenously in subtenon block.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>75 Patients were assigned into three equal groups, all patients received 2.5 ml of local anesthetic mixture through subtenon block and IV infusion of drugs as follows: Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.&#xD;
Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.&#xD;
Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of sensory block</measure>
    <time_frame>24 hours</time_frame>
    <description>time from injection of local anesthetic mixture to complete recovery from pain sensation or the first need of rescue analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of motor block</measure>
    <time_frame>24 hours</time_frame>
    <description>time from injection of local anesthetic to complete recovery of motor function in all ocular muscles.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acute Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group C (control group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group SD (subtenon dexmedetomiine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ID (iv dexmedetomidine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>the drug administered either subtenon ot iv</description>
    <arm_group_label>Group ID (iv dexmedetomidine)</arm_group_label>
    <arm_group_label>Group SD (subtenon dexmedetomiine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine 2%</intervention_name>
    <description>subtenon injection</description>
    <arm_group_label>Group C (control group)</arm_group_label>
    <arm_group_label>Group ID (iv dexmedetomidine)</arm_group_label>
    <arm_group_label>Group SD (subtenon dexmedetomiine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacine 0.5%</intervention_name>
    <description>subtenon injection</description>
    <arm_group_label>Group C (control group)</arm_group_label>
    <arm_group_label>Group ID (iv dexmedetomidine)</arm_group_label>
    <arm_group_label>Group SD (subtenon dexmedetomiine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>either subtenon or iv</description>
    <arm_group_label>Group C (control group)</arm_group_label>
    <arm_group_label>Group SD (subtenon dexmedetomiine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA grade I-III&#xD;
&#xD;
          -  Aged 18-70 years&#xD;
&#xD;
          -  Both sex&#xD;
&#xD;
          -  Scheduled for elective phacoemulsification cataract surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulation abnormalities&#xD;
&#xD;
          -  Impaired mental status&#xD;
&#xD;
          -  Refusal of the patient&#xD;
&#xD;
          -  Uncontrolled glaucoma&#xD;
&#xD;
          -  Recent surgical procedure on the same eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ashraf magdy Eskandr</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufiya</state>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osama A Elmorsy</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufiya</state>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadik A Sadik</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufiya</state>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>ashraf magdy eskandr</investigator_full_name>
    <investigator_title>assistant professor of anesthesia, icu</investigator_title>
  </responsible_party>
  <keyword>subtenon</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

